%PDF-1.4 %âãÏÓ 1 0 obj << /Type /Catalog /Pages 2 0 R >> endobj 2 0 obj << /Type /Pages /Count 7 /Kids [5 0 R 7 0 R 9 0 R 11 0 R 13 0 R 15 0 R 17 0 R] >> endobj 3 0 obj << /Type /Font /Subtype /Type1 /BaseFont /Helvetica >> endobj 4 0 obj << /Type /Font /Subtype /Type1 /BaseFont /Helvetica-Bold >> endobj 5 0 obj << /Type /Page /Parent 2 0 R /MediaBox [0 0 595.28 841.89] /Resources << /Font << /F1 3 0 R /F2 4 0 R >> >> /Contents 6 0 R >> endobj 6 0 obj << /Length 5552 >> stream BT /F2 22 Tf 0.06 0.08 0.12 rg 1 0 0 1 46 789.89 Tm (4 Best AI Drug Discovery Platforms for 2026) Tj ET BT /F2 11 Tf 0.72 0.14 0.18 rg 1 0 0 1 46 752.89 Tm (TechRounder PDF Edition) Tj ET BT /F1 9.5 Tf 0.36 0.39 0.46 rg 1 0 0 1 46 736.89 Tm (Live article: https://www.techrounder.com/tools/4-best-ai-drug-discovery-platforms-for-2026/) Tj ET q 0.82 0.85 0.9 RG 1 w 46 718.39 m 549.28 718.39 l S Q BT /F1 10 Tf 0.24 0.27 0.32 rg 1 0 0 1 46 706.39 Tm (By Vipin PG | Published August 7, 2026 | Updated August 7, 2026 | Format: Deep Dive | 9 min read) Tj ET BT /F2 13 Tf 0.72 0.14 0.18 rg 1 0 0 1 46 683.39 Tm (In brief) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 663.39 Tm (Modern AI drug discovery platforms are transforming pharmaceutical R&D by integrating multimodal) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 648.39 Tm (biological data and generative AI to accelerate target identification and molecular design. By shifting the) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 633.39 Tm (focus from trial-and-error to high-confidence hypothesis validation, these tools reduce the time and) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 618.39 Tm (capital required to bring new therapies from scientific theory to approved medicine.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 593.39 Tm (Bringing a new therapy from scientific hypothesis to approved medicine has always required) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 578.39 Tm (extraordinary amounts of time, capital, and experimentation. Researchers must identify promising) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 563.39 Tm (biological targets, understand disease mechanisms, design candidate molecules, evaluate safety) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 548.39 Tm (profiles, and refine compounds through multiple rounds of laboratory testing before a potential drug) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 533.39 Tm (ever reaches clinical trials. At every stage, uncertainty is high, and only a small fraction of candidates) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 518.39 Tm (ultimately succeed.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 496.39 Tm (The field has also evolved considerably over the past few years. Early AI applications focused on) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 481.39 Tm (individual tasks such as virtual screening or molecular generation. Today's leading platforms combine) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 466.39 Tm (multiple AI models with biological data, computational chemistry, protein science, and laboratory) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 451.39 Tm (validation into integrated discovery environments capable of supporting much larger portions of the) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 436.39 Tm (drug discovery pipeline.) Tj ET BT /F2 15 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 408.39 Tm (At a Glance) Tj ET BT /F1 10 Tf 0.18 0.2 0.24 rg 1 0 0 1 46 384.39 Tm (Platform | Best For) Tj ET BT /F1 10 Tf 0.18 0.2 0.24 rg 1 0 0 1 46 367.39 Tm (Converge | Multimodal AI for end-to-end biological discovery) Tj ET BT /F1 10 Tf 0.18 0.2 0.24 rg 1 0 0 1 46 350.39 Tm (Isomorphic Labs | Protein modeling and AI-driven therapeutic research) Tj ET BT /F1 10 Tf 0.18 0.2 0.24 rg 1 0 0 1 46 333.39 Tm (Recursion | AI-powered phenomics and experimental biology) Tj ET BT /F1 10 Tf 0.18 0.2 0.24 rg 1 0 0 1 46 316.39 Tm (Insilico Medicine | Generative AI for target discovery and molecule design) Tj ET BT /F2 15 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 293.39 Tm (4 Best AI Drug Discovery Platforms) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 263.39 Tm (1. Converge) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 241.39 Tm (Converge is building an AI-native platform designed to help researchers understand biology at a) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 226.39 Tm (deeper level and translate that understanding into more efficient drug discovery. Rather than focusing) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 211.39 Tm (on a single stage of pharmaceutical research, the platform applies multimodal artificial intelligence to) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 196.39 Tm (integrate diverse biological information, allowing scientists to explore complex disease mechanisms) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 181.39 Tm (and identify promising therapeutic opportunities with greater confidence.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 159.39 Tm (A key strength of Converge is its ability to combine multiple forms of biological data into unified) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 144.39 Tm (computational models. Modern drug discovery depends on far more than molecular structures alone.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 129.39 Tm (Researchers must interpret genomic information, protein interactions, biological pathways,) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 114.39 Tm (experimental observations, and scientific literature simultaneously. Converge's AI models are) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 99.39 Tm (designed to reason across these interconnected datasets, providing richer biological context than) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 84.39 Tm (isolated prediction models.) Tj ET q 0.86 0.88 0.92 RG 1 w 46 42 m 549.28 42 l S Q BT /F1 8.4 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 30 Tm (TechRounder | Page 1 of 7) Tj ET BT /F1 7.2 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 19 Tm (https://www.techrounder.com/pdf/blog/4-best-ai-drug-discovery-platforms-for-2026.pdf) Tj ET endstream endobj 7 0 obj << /Type /Page /Parent 2 0 R /MediaBox [0 0 595.28 841.89] /Resources << /Font << /F1 3 0 R /F2 4 0 R >> >> /Contents 8 0 R >> endobj 8 0 obj << /Length 5289 >> stream BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 789.89 Tm (The platform also emphasizes scalable scientific workflows that support iterative discovery. Instead) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 774.89 Tm (of treating AI as a standalone prediction engine, Converge enables researchers to continuously refine) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 759.89 Tm (hypotheses as new experimental evidence becomes available. This creates a feedback loop where) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 744.89 Tm (computational insights and laboratory validation strengthen one another throughout the discovery) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 729.89 Tm (process.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 707.89 Tm (Another distinguishing characteristic is explainability. Drug discovery decisions require scientific) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 692.89 Tm (justification rather than black-box predictions. Converge helps researchers trace AI-generated) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 677.89 Tm (recommendations back to the biological evidence supporting them, allowing scientists to evaluate) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 662.89 Tm (hypotheses alongside the underlying data before committing laboratory resources.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 640.89 Tm (For pharmaceutical companies, biotechnology organizations, and research institutions seeking to) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 625.89 Tm (accelerate early-stage R&D, Converge provides a comprehensive AI platform that combines) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 610.89 Tm (multimodal biology, machine learning, and scientific reasoning to support more informed discovery) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 595.89 Tm (decisions.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 573.89 Tm (Key features) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 551.89 Tm (- Multimodal biological AI) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 535.09 Tm (- Foundation biological models) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 518.29 Tm (- Target discovery) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 501.49 Tm (- Biological reasoning) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 484.69 Tm (- Molecular representation learning) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 467.89 Tm (- Explainable AI) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 451.09 Tm (- End-to-end discovery workflows) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 428.29 Tm (2. Isomorphic Labs) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 406.29 Tm (Isomorphic Labs applies advanced artificial intelligence to biological research with the goal of) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 391.29 Tm (accelerating the discovery of new medicines. Building on expertise in machine learning and structural) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 376.29 Tm (biology, the company develops AI systems capable of modeling complex biological processes that) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 361.29 Tm (influence therapeutic development.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 339.29 Tm (Protein structure prediction remains one of its most recognized areas of innovation. Understanding) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 324.29 Tm (how proteins fold and interact provides researchers with valuable insight into disease mechanisms,) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 309.29 Tm (target biology, and molecular interactions that are fundamental to drug discovery. AI-driven structural) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 294.29 Tm (modeling allows scientists to investigate biological questions more rapidly than traditional computational) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 279.29 Tm (approaches alone.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 257.29 Tm (Beyond protein modeling, the platform supports broader therapeutic research by integrating biological) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 242.29 Tm (knowledge with computational analysis. Researchers can evaluate molecular interactions, investigate) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 227.29 Tm (potential drug targets, and prioritize promising research directions before committing significant) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 212.29 Tm (laboratory resources.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 190.29 Tm (Key features) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 168.29 Tm (- Protein structure modeling) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 151.49 Tm (- AI biology) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 134.69 Tm (- Target analysis) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 117.89 Tm (- Molecular prediction) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 101.09 Tm (- Structural biology) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 84.29 Tm (- Pharmaceutical collaboration) Tj ET q 0.86 0.88 0.92 RG 1 w 46 42 m 549.28 42 l S Q BT /F1 8.4 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 30 Tm (TechRounder | Page 2 of 7) Tj ET BT /F1 7.2 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 19 Tm (https://www.techrounder.com/pdf/blog/4-best-ai-drug-discovery-platforms-for-2026.pdf) Tj ET endstream endobj 9 0 obj << /Type /Page /Parent 2 0 R /MediaBox [0 0 595.28 841.89] /Resources << /Font << /F1 3 0 R /F2 4 0 R >> >> /Contents 10 0 R >> endobj 10 0 obj << /Length 5126 >> stream BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 789.89 Tm (- Computational drug discovery) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 767.09 Tm (3. Recursion) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 745.09 Tm (Recursion combines artificial intelligence, automation, and experimental biology to create one of the) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 730.09 Tm (largest phenomics-driven drug discovery platforms in the industry. Rather than relying exclusively on) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 715.09 Tm (computational predictions, the company integrates large-scale laboratory experimentation with) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 700.09 Tm (machine learning models trained on extensive biological datasets.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 678.09 Tm (A defining capability of the platform is its use of high-throughput imaging and computer vision to) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 663.09 Tm (analyze cellular behavior. Millions of experimental observations are converted into quantitative) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 648.09 Tm (biological data, enabling AI models to detect subtle phenotypic patterns that may indicate promising) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 633.09 Tm (therapeutic opportunities.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 611.09 Tm (This integration of automated experimentation and machine learning allows researchers to evaluate) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 596.09 Tm (biological hypotheses across large datasets while continuously improving predictive models as) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 581.09 Tm (additional laboratory results become available.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 559.09 Tm (Key features) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 537.09 Tm (- Phenomics platform) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 520.29 Tm (- Automated experimentation) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 503.49 Tm (- Computer vision) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 486.69 Tm (- Biological imaging) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 469.89 Tm (- Machine learning) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 453.09 Tm (- Large-scale biological datasets) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 436.29 Tm (- Closed-loop discovery) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 413.49 Tm (4. Insilico Medicine) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 391.49 Tm (Insilico Medicine has established itself as one of the leading developers of generative AI technologies) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 376.49 Tm (for pharmaceutical research. The platform applies machine learning across multiple stages of early) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 361.49 Tm (drug discovery, helping researchers identify biological targets, generate novel molecular structures,) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 346.49 Tm (and optimize therapeutic candidates before laboratory testing.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 324.49 Tm (Generative AI plays a central role in its discovery workflow. Rather than limiting researchers to) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 309.49 Tm (existing compound libraries, the platform can propose entirely new molecular candidates designed to) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 294.49 Tm (satisfy specific biological and chemical objectives. This expands the range of potential therapeutic) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 279.49 Tm (options available during early-stage discovery.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 257.49 Tm (The platform also supports target discovery by integrating biological data with AI models capable of) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 242.49 Tm (identifying disease-related mechanisms that may warrant further investigation. Once promising) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 227.49 Tm (targets have been identified, computational chemistry tools assist researchers in refining candidate) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 212.49 Tm (molecules to improve desirable characteristics before synthesis and laboratory evaluation.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 190.49 Tm (Key features) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 168.49 Tm (- Generative chemistry) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 151.69 Tm (- Target discovery) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 134.89 Tm (- Molecule generation) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 118.09 Tm (- Lead optimization) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 101.29 Tm (- AI drug design) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 84.49 Tm (- Predictive modeling) Tj ET q 0.86 0.88 0.92 RG 1 w 46 42 m 549.28 42 l S Q BT /F1 8.4 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 30 Tm (TechRounder | Page 3 of 7) Tj ET BT /F1 7.2 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 19 Tm (https://www.techrounder.com/pdf/blog/4-best-ai-drug-discovery-platforms-for-2026.pdf) Tj ET endstream endobj 11 0 obj << /Type /Page /Parent 2 0 R /MediaBox [0 0 595.28 841.89] /Resources << /Font << /F1 3 0 R /F2 4 0 R >> >> /Contents 12 0 R >> endobj 12 0 obj << /Length 6465 >> stream BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 789.89 Tm (- Computational biology) Tj ET BT /F2 15 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 767.09 Tm (The Characteristics Shared by Leading AI Drug Discovery Platforms) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 743.09 Tm (Although AI drug discovery platforms differ in their scientific approaches, the strongest solutions) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 728.09 Tm (share several capabilities that consistently support more effective pharmaceutical research.) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 706.09 Tm (- Multimodal biological understanding has become increasingly important. Rather than analyzing a single) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 692.29 Tm (data type, leading platforms integrate genomic information, protein structures, molecular interactions,) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 678.49 Tm (biomedical literature, imaging data, and experimental results into unified models that provide richer) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 664.69 Tm (biological context.) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 647.89 Tm (- High-quality proprietary and public datasets also play a critical role. AI models are only as effective as) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 634.09 Tm (the biological information used to train them. Successful platforms combine diverse, well-curated datasets) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 620.29 Tm (with robust data management practices to improve predictive performance.) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 603.49 Tm (- Explainable predictions are another defining characteristic. Researchers need to understand why an AI) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 589.69 Tm (model recommends a particular target or molecule before investing laboratory resources. Platforms that) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 575.89 Tm (provide transparent reasoning and traceable evidence help scientists evaluate AI-generated hypotheses) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 562.09 Tm (more confidently.) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 545.29 Tm (- Integration with experimental workflows remains essential. Drug discovery ultimately depends on) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 531.49 Tm (laboratory validation, making seamless collaboration between computational predictions and wet-lab) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 517.69 Tm (experimentation a major advantage. The strongest platforms are designed to support iterative feedback) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 503.89 Tm (between AI models and biological experiments rather than treating computation as an isolated activity.) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 487.09 Tm (- Scalable automation also distinguishes mature solutions. Automated data processing, molecular analysis,) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 473.29 Tm (hypothesis generation, and experimental prioritization allow research organizations to investigate) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 459.49 Tm (significantly larger biological spaces than would be feasible through manual methods alone.) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 442.69 Tm (- C ontinuous learning has become an increasingly valuable capability. As new experimental results become) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 428.89 Tm (available, advanced AI platforms can incorporate additional biological evidence into future predictions,) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 415.09 Tm (helping discovery programs improve over time while adapting to new scientific knowledge.) Tj ET BT /F2 15 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 392.29 Tm (Why AI Is Changing the Economics of Drug Discovery) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 368.29 Tm (Drug discovery has never lacked scientific ambition.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 346.29 Tm (Its greatest limitation has always been efficiency.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 324.29 Tm (Developing a new therapeutic candidate requires evaluating enormous numbers of biological) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 309.29 Tm (hypotheses while navigating complex interactions between genes, proteins, pathways, cells, tissues,) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 294.29 Tm (and disease mechanisms. Even after years of research, many promising compounds fail because) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 279.29 Tm (they do not demonstrate sufficient efficacy or acceptable safety profiles.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 257.29 Tm (The financial implications are equally significant.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 235.29 Tm (Each unsuccessful candidate represents years of laboratory work, computational modeling,) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 220.29 Tm (experimental validation, and clinical preparation. Reducing failure rates-even modestly-can have a) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 205.29 Tm (substantial impact on research productivity and development costs.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 183.29 Tm (Artificial intelligence addresses this challenge by helping scientists prioritize better experiments) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 168.29 Tm (rather than simply performing more experiments.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 146.29 Tm (Instead of evaluating every possible biological pathway manually, AI models can identify patterns) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 131.29 Tm (hidden within genomic datasets, biomedical literature, protein structures, imaging data, molecular) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 116.29 Tm (interactions, and clinical evidence. Researchers can then focus laboratory resources on the) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 101.29 Tm (hypotheses most likely to produce meaningful scientific results.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 79.29 Tm (This shift changes the economics of discovery in several ways:) Tj ET q 0.86 0.88 0.92 RG 1 w 46 42 m 549.28 42 l S Q BT /F1 8.4 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 30 Tm (TechRounder | Page 4 of 7) Tj ET BT /F1 7.2 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 19 Tm (https://www.techrounder.com/pdf/blog/4-best-ai-drug-discovery-platforms-for-2026.pdf) Tj ET endstream endobj 13 0 obj << /Type /Page /Parent 2 0 R /MediaBox [0 0 595.28 841.89] /Resources << /Font << /F1 3 0 R /F2 4 0 R >> >> /Contents 14 0 R >> endobj 14 0 obj << /Length 4756 >> stream BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 789.89 Tm (- Faster biological target identification) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 773.09 Tm (- More efficient lead optimization) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 756.29 Tm (- Improved prediction of molecular properties) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 739.49 Tm (- Better prioritization of experimental candidates) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 722.69 Tm (- Reduced reliance on trial-and-error workflows) Tj ET BT /F1 10.5 Tf 0.2 0.23 0.28 rg 1 0 0 1 46 705.89 Tm (- Greater scalability across therapeutic programs) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 689.09 Tm (Importantly, AI does not eliminate laboratory experimentation.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 667.09 Tm (Wet-lab validation remains essential because biological systems are extraordinarily complex.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 652.09 Tm (Computational predictions must ultimately be confirmed through carefully designed experiments) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 637.09 Tm (before they can support drug development decisions.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 615.09 Tm (Instead, AI enables laboratories to spend less time searching for promising directions and more time) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 600.09 Tm (validating high-confidence scientific hypotheses.) Tj ET BT /F2 15 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 572.09 Tm (Where AI Delivers the Greatest Scientific Impact) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 548.09 Tm (Artificial intelligence contributes value throughout multiple stages of drug discovery, but its impact is) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 533.09 Tm (particularly significant in several key scientific workflows.) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 505.09 Tm (Target Identification) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 483.09 Tm (Selecting the right biological target is one of the most important decisions in drug discovery.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 461.09 Tm (AI models analyze genomic data, disease biology, scientific literature, and molecular networks to) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 446.09 Tm (identify proteins or pathways that may play important roles in disease progression, allowing) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 431.09 Tm (researchers to prioritize targets with stronger biological evidence.) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 403.09 Tm (Biomarker Discovery) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 381.09 Tm (Modern machine learning techniques help identify biomarkers associated with disease diagnosis,) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 366.09 Tm (treatment response, or patient stratification.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 344.09 Tm (These discoveries support precision medicine while improving clinical trial design.) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 316.09 Tm (Molecular Generation) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 294.09 Tm (Generative AI can propose novel molecular structures that satisfy predefined biological and chemical) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 279.09 Tm (objectives.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 257.09 Tm (Rather than screening only existing compound libraries, researchers can explore entirely new areas) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 242.09 Tm (of chemical space for potential therapeutics.) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 214.09 Tm (Lead Optimization) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 192.09 Tm (After identifying promising compounds, AI models help optimize molecular properties by balancing) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 177.09 Tm (potency, selectivity, stability, and manufacturability while minimizing undesirable characteristics.) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 149.09 Tm (ADMET Prediction) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 127.09 Tm (Predicting absorption, distribution, metabolism, excretion, and toxicity \(ADMET\) early in development) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 112.09 Tm (allows researchers to eliminate weaker candidates before investing in expensive laboratory studies.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 90.09 Tm (Machine learning significantly accelerates this evaluation process.) Tj ET q 0.86 0.88 0.92 RG 1 w 46 42 m 549.28 42 l S Q BT /F1 8.4 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 30 Tm (TechRounder | Page 5 of 7) Tj ET BT /F1 7.2 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 19 Tm (https://www.techrounder.com/pdf/blog/4-best-ai-drug-discovery-platforms-for-2026.pdf) Tj ET endstream endobj 15 0 obj << /Type /Page /Parent 2 0 R /MediaBox [0 0 595.28 841.89] /Resources << /Font << /F1 3 0 R /F2 4 0 R >> >> /Contents 16 0 R >> endobj 16 0 obj << /Length 5386 >> stream BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 789.89 Tm (Candidate Prioritization) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 767.89 Tm (Perhaps the greatest benefit comes from integrating multiple sources of biological evidence into a) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 752.89 Tm (single decision-making framework.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 730.89 Tm (Rather than evaluating isolated datasets independently, modern AI platforms help researchers) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 715.89 Tm (prioritize drug candidates using a broader understanding of disease biology, molecular interactions,) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 700.89 Tm (and experimental evidence.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 678.89 Tm (Drug discovery will always require rigorous experimental validation, regulatory oversight, and) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 663.89 Tm (scientific judgment. However, as multimodal AI, foundation models, robotics, and automated) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 648.89 Tm (experimentation continue to mature, researchers will gain increasingly powerful tools for navigating) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 633.89 Tm (biological complexity and accelerating the search for new therapeutics.) Tj ET BT /F2 15 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 605.89 Tm (Frequently Asked Questions) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 575.89 Tm (What is an AI drug discovery platform?) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 553.89 Tm (An AI drug discovery platform uses artificial intelligence to support pharmaceutical research by) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 538.89 Tm (analyzing biological data, identifying potential drug targets, generating molecular candidates, predicting) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 523.89 Tm (molecular properties, and helping researchers prioritize experiments. These platforms are designed) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 508.89 Tm (to accelerate early-stage discovery while improving scientific decision-making.) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 480.89 Tm (Can AI discover drugs without laboratory experiments?) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 458.89 Tm (No. AI can generate hypotheses, predict molecular behavior, and prioritize promising candidates, but) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 443.89 Tm (laboratory validation remains essential. Experimental studies are required to confirm biological) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 428.89 Tm (activity, evaluate safety, assess efficacy, and generate the evidence needed before drug candidates) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 413.89 Tm (can progress through development.) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 385.89 Tm (Which stages of drug discovery benefit most from AI?) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 363.89 Tm (AI provides value across several stages of drug discovery, including target identification, biomarker) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 348.89 Tm (discovery, molecular generation, lead optimization, ADMET prediction, and candidate prioritization.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 333.89 Tm (Many modern platforms support multiple stages of the discovery pipeline rather than focusing on a) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 318.89 Tm (single computational task.) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 290.89 Tm (Does AI replace medicinal chemists or biologists?) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 268.89 Tm (No. AI is designed to augment scientific expertise rather than replace it. Researchers remain) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 253.89 Tm (responsible for interpreting biological evidence, designing experiments, validating computational) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 238.89 Tm (predictions, and making critical scientific decisions throughout the drug discovery process. AI helps) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 223.89 Tm (automate data analysis and identify promising research directions but does not replace domain) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 208.89 Tm (expertise.) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 180.89 Tm (Why is multimodal biology important in AI drug discovery?) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 158.89 Tm (Biological systems are influenced by many interconnected factors, including genes, proteins, cells,) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 143.89 Tm (tissues, molecular interactions, and clinical observations. Multimodal AI integrates these diverse data) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 128.89 Tm (types into unified models, allowing researchers to develop a more comprehensive understanding of) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 113.89 Tm (disease biology than would be possible using isolated datasets alone.) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 85.89 Tm (How much can AI accelerate drug discovery?) Tj ET q 0.86 0.88 0.92 RG 1 w 46 42 m 549.28 42 l S Q BT /F1 8.4 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 30 Tm (TechRounder | Page 6 of 7) Tj ET BT /F1 7.2 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 19 Tm (https://www.techrounder.com/pdf/blog/4-best-ai-drug-discovery-platforms-for-2026.pdf) Tj ET endstream endobj 17 0 obj << /Type /Page /Parent 2 0 R /MediaBox [0 0 595.28 841.89] /Resources << /Font << /F1 3 0 R /F2 4 0 R >> >> /Contents 18 0 R >> endobj 18 0 obj << /Length 1932 >> stream BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 789.89 Tm (The impact varies depending on the therapeutic area, available biological data, and research objectives.) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 774.89 Tm (AI has the potential to shorten parts of the early discovery process by improving target prioritization,) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 759.89 Tm (reducing unnecessary experiments, accelerating molecular design, and helping researchers focus) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 744.89 Tm (laboratory resources on higher-confidence hypotheses.) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 716.89 Tm (What should organizations evaluate when selecting an AI drug discovery platform?) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 694.89 Tm (Organizations should consider the platform's biological modeling capabilities, support for multimodal) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 679.89 Tm (data, explainability, integration with laboratory workflows, scalability, quality of underlying datasets,) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 664.89 Tm (automation features, and ability to support collaborative research across computational and) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 649.89 Tm (experimental teams. The most effective platforms combine strong AI capabilities with workflows that) Tj ET BT /F1 11 Tf 0.14 0.16 0.2 rg 1 0 0 1 46 634.89 Tm (complement established scientific research practices.) Tj ET BT /F2 13 Tf 0.08 0.1 0.14 rg 1 0 0 1 46 606.89 Tm (References) Tj ET BT /F1 10 Tf 0.18 0.2 0.24 rg 1 0 0 1 46 586.89 Tm (1. converge-bio.com - https://converge-bio.com/) Tj ET q 0.86 0.88 0.92 RG 1 w 46 42 m 549.28 42 l S Q BT /F1 8.4 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 30 Tm (TechRounder | Page 7 of 7) Tj ET BT /F1 7.2 Tf 0.42 0.45 0.5 rg 1 0 0 1 46 19 Tm (https://www.techrounder.com/pdf/blog/4-best-ai-drug-discovery-platforms-for-2026.pdf) Tj ET endstream endobj xref 0 19 0000000000 65535 f 0000000015 00000 n 0000000064 00000 n 0000000161 00000 n 0000000231 00000 n 0000000306 00000 n 0000000448 00000 n 0000006051 00000 n 0000006193 00000 n 0000011533 00000 n 0000011676 00000 n 0000016854 00000 n 0000016998 00000 n 0000023515 00000 n 0000023659 00000 n 0000028467 00000 n 0000028611 00000 n 0000034049 00000 n 0000034193 00000 n trailer << /Size 19 /Root 1 0 R >> startxref 36177 %%EOF